BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 76 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $8,974,000 | -42.9% | 239,000 | -39.9% | 0.32% | -41.8% |
Q2 2018 | $15,729,000 | -29.7% | 398,000 | -54.2% | 0.55% | -28.9% |
Q1 2018 | $22,385,000 | +143.3% | 869,000 | +154.8% | 0.78% | +114.4% |
Q4 2017 | $9,200,000 | +49.2% | 341,000 | +106.7% | 0.36% | +30.2% |
Q3 2017 | $6,168,000 | +13.8% | 165,000 | -23.9% | 0.28% | -3.8% |
Q2 2017 | $5,419,000 | – | 216,761 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |